Valuation: LOTUS PHARM

Market Cap 97.36L 85.44L 79.56L 73.18L 1.37Cr 93Cr 1.4Cr 9.44Cr 3.69Cr 46Cr 3.65Cr 3.58Cr 159.37Cr P/E 2009
3.88x
P/E 2010 4.84x
Enterprise Value 1.44Cr 1.26Cr 1.18Cr 1.08Cr 2.03Cr 137.41Cr 2.06Cr 14Cr 5.46Cr 68Cr 5.4Cr 5.28Cr 235.44Cr EV / Sales 2009
1.02x
EV / Sales 2010 0.95x
Free-Float
99%
Yield 2009 *
-
Yield 2010 -
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+1.04%+16.34%+74.17% 4.94TCr
+0.53%+3.50%+61.24%+112.76% 3.63TCr
+2.50%+0.21%-5.74%+23.32% 1.19TCr
-0.81%-4.33%+12.58%+69.24% 1.15TCr
+0.38%-2.06%+34.70%+131.86% 898.9Cr
-0.92%-0.35%+48.24%-9.27% 700.4Cr
-0.51%-0.85%+11.77%+33.26% 676.17Cr
-0.52%-2.45%+1.83%+165.65% 646.21Cr
-1.32%-11.87%-32.46%-0.24% 548.53Cr
Average -0.06%-0.95%+16.50%+66.75% 1.6TCr
Weighted average by Cap. +0.21%+0.32%+25.54%+78.22%

Financials

2009 2010
Net sales 5.78Cr 5.07Cr 4.73Cr 4.35Cr 8.15Cr 552.44Cr 8.29Cr 56Cr 22Cr 273.97Cr 22Cr 21Cr 946.57Cr 7.27Cr 6.38Cr 5.94Cr 5.46Cr 10Cr 694.52Cr 10Cr 70Cr 28Cr 344.43Cr 27Cr 27Cr 1.19TCr
Net income 1.64Cr 1.44Cr 1.34Cr 1.24Cr 2.32Cr 156.99Cr 2.36Cr 16Cr 6.24Cr 78Cr 6.17Cr 6.04Cr 268.99Cr 1.44Cr 1.27Cr 1.18Cr 1.08Cr 2.03Cr 137.81Cr 2.07Cr 14Cr 5.47Cr 68Cr 5.42Cr 5.3Cr 236.13Cr
Net Debt 5.29 4.65 4.33 3.98 7.46 505.76 7.59 51.33 20.09 250.82 19.87 19.44 866.59 4.65 4.08 3.8 3.49 6.55 443.93 6.66 45.05 17.63 220.16 17.44 17.07 760.66
Logo LOTUS PHARM
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
-